News


2022-12-01 09:56:22 | 535
INCEPTA Pharmaceuticals Ltd is proud to become one of the 27 companies to sign licensing agreement with the Medicines Patent Pool (MPP)

INCEPTA Pharmaceuticals Ltd is proud to become one of the 27 companies to sign licensing agreement with the Medicines Patent Pool (MPP) to manufacture the generic version of the oral COVID-19 antiviral medication Molnupiravir for supply in 105 low- and-middle-income countries (LMICs).

Premia Biotech Ltd
Mobile / WhatsApp : +44 7887 477007
Email : info@premiabiotech.com

https://lnkd.in/gZTzg-pW

#covid #molnupiravir #genericdrugs #antiviral #pharmaceuticalsales #premiabiotech

TESTIMONIALS